AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

FDA approves first combination pill to treat hepatitis C

FDA

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs…

Gay and Bisexual Men See HIV as the Top Health Issue Facing Their Community, But Majorities Are Not Personally Worried About Getting Infected & Not Getting Tested Regularly

kff-logo

Most Are Unaware of New Prevention Options, Such as PrEP, or Current Treatment Recommendations MENLO PARK, CA – More than thirty years into the HIV/AIDS epidemic, and at a time when infections among gay and bisexual men are on the rise in the U.S., a new national survey  of gay and bisexual men by the Kaiser Family Foundation…

Puerto Rico Makes Important Strides To Support Vaccine Research to Combat HIV

pr

The Obama Administration is a strong partner in helping Puerto Rico to develop the industries that will support its long-term economic growth. One such opportunity is to work through the President’s Task Force on Puerto Rico to identify opportunities can work more closely with partners to ensure that Puerto Rico’s best days are ahead. Earlier…

Researchers Find Hepatitis C Cures Effective for People Living with HIV/HCV Coinfection – Reports from AIDS 2014

Dr. M. Sulkowski and Dr. J. Molina discuss HIV-HCV coinfection study findings at AIDS 2014. Photo Courtesy of the International AIDS Foundation

The World Health Organization estimates that globally, 5-15% of people living with HIV are coinfected with hepatitis C. In the United States, about 25% of people living with HIV also have hepatitis C (HCV)—and HCV rates are even higher among people with HIV who inject drugs. For both hepatitis B and hepatitis C infection, disease…

Faster, Easier Cures for Hepatitis C

ucm405643

Transformative advances in drug treatments approved by the Food and Drug Administration are giving the 3.2 million Americans with chronic hepatitis C a chance for a longer, healthier life without the virus. That’s welcome news for baby boomers—who make up three of four adults with the hepatitis C virus—and millions of other Americans, many of…

NIH’s Dr. Carl Dieffenbach Shares Final Thoughts from AIDS 2014

aids 2014

As the 20th International AIDS Conference (AIDS 2014) drew to a close in Melbourne, Australia, we asked Dr. Carl Dieffenbach from NIH/NIAIDto provide a summary of conference highlights. Dr. Dieffenbach recognized the Malaysia Airlines tragedy, a loss deeply felt by those in the worldwide HIV community. He noted that the conference theme of “stepping up…

NIH’s Dr. Gina Brown Reflects on HIV Among Women and Girls –Highlights from AIDS 2014

gina_brown

Addressing HIV/AIDS among women and girls was a key focus area of many sessions at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia. Presenters covered such important topics as HIV prevention interventions for women and girls, the prevention of mother-to-child transmission, and enhancing HIV care and treatment for women and girls. To learn…

NIH’s Dr. Carl Dieffenbach Shares Highlights from Thursday at AIDS 2014

carl

At the conclusion of Thursday’s sessions at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia, we spoke again with Dr. Carl Dieffenbach from NIH/NIAID to hear his summary of conference highlights of the day. Dr. Dieffenbach observed that much of the conversation on Thursday was around advances in HIV prevention and how to optimize…